Isomab

IsomAb is a pre-clinical stage biotechnology company focused on developing isoform-specific, humanized IgG1 antibodies to treat diseases where patients currently have limited treatment options. The company operates in the biopharmaceutical market, targeting diseases at the molecular level rather than merely addressing symptoms. Its core product, vexobicizumab, is designed to inhibit the VEGF A165b isoform, which is crucial in preventing collateral vessel formation in ischemic diseases. IsomAb's business model revolves around extensive research and development, aiming to bring its first product into clinical trials by 2026. The company generates revenue through partnerships, grants, and future commercialization of its antibody therapies. IsomAb serves a niche market of patients with specific vascular and ischemic conditions, leveraging over 20 years of research to provide innovative treatment solutions.

Keywords: isoform-specific antibodies, humanized IgG1, VEGF A165b, ischemic diseases, pre-clinical stage, biopharmaceutical, molecular targeting, vascular conditions, antibody therapies, niche market.